Immunotherapy

The most recent articles from: Immunotherapy November 2018

Immunotherapy · Nov 2018

Meta Analysis

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.

We aimed to assess the incidence and relative risk (RR) of fatigue in cancer patients treated with anti programmed cell death-1 (PD-1) and anti programmed cell death ligand-1 (PD-L1) agents. ⋯ Treatment with anti-PD-1/PD-L1 agents correlates with lower incidence and RR of fatigue compared with standard therapies.

expand abstract… mark as read…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.